Common mechanisms of secondary endocrine resistance in advanced ER+ breast cancer

Common mechanisms of secondary endocrine resistance in advanced ER+ breast cancer. Aberrant activation of RTKs (HER2, IGFR1, FGFR, EGFR) by mutations or amplifications leads to activation of the PI3K and MAPK signaling pathways. NF1 loss-of-function mutations result in constitutively active RAS leading to downstream activation of both PI3K and MAPK pathways. PI3K and MAPK pathways activation induces ER phosphorylation and ligand-independent activation leading to transcription of ER-regulated genes despite estrogen blockade with endocrine therapy. Targeting upstream activation of RTKs (FGFR inhibition) or downstream oncogenic proteins of the PI3K pathway (AKT inhibition) and MAPK pathway (ERK inhibition) provides therapeutic options that can potentially overcome secondary endocrine resistance when combined with antiestrogen therapy. Point mutations of ER (ESR1 mutations) are another common mechanism of endocrine resistance rendering aromatase inhibitors ineffective. Oral SERDs ± targeted therapies present as an effective treatment option in ESR1 mutated tumors. CERANs, SERCAs, ShERPAs, and PROTACs are novel agents with therapeutic potential to overcome resistance to traditional endocrine therapies and are under development. NOTCH signaling upregulation has been shown to promote breast cancer stem-like cell expansion and its pharmacologic disruption can lead to reversal of resistance to antiestrogen therapy. AURKA overactivation has been linked to downregulation of estrogen receptors leading to endocrine resistance and worse prognosis. Novel agents targeting AURKA are being investigated as a potential therapeutic approach to overcome endocrine resistance. Abbreviations: AURKA, aurora kinase A; BRAF, v-raf murine sarcoma viral oncogene homolog B1; CERAN, Complete Estrogen Receptor Antagonist; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; ER, estrogen receptor; ERE, estrogen receptor element; FGFR, fibroblast growth factor receptor; GTP, Guanosine-5’-triphosphate; HRAS, Hras proto-oncogene; HER, human epidermal growth factors receptor; IGFR, insulin-like growth factor; KRAS, Kirsten rat sarcoma virus; mTOR, mammalian target of rapamycin; MAP2K, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase kinase; NOTCH, notch signaling pathway; NF, nuclear factor; NRAS, neuroblastoma RAS viral oncogene Humalog; PROTAC, Proteolysis Targeting Chimera; PI3K, phosphoinositide 3-kinases; PTEN, phosphatase and TENsin homolog; RAS rat sarcoma signaling; Raf, rapidly accelerated fibrosarcoma; ShERPA, selective human estrogen receptor partial agonist; SERCA, selective estrogen receptor covalent antagonist
Common mechanisms of secondary endocrine resistance in advanced ER+ breast cancer

Publication

Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches (2023) Farah Raheem, et al. Int J Mol Sci. 2023 Nov;24(22). Figure: F2.

Gene mentions


Organism Group Word Match Source NCBI Symbol NCBI ID
Homo sapiens Primates HER2 HER2 ncbigene_synonym ERBB2 2064
Homo sapiens Primates PTEN PTEN ncbigene_symbol PTEN 5728
Homo sapiens Primates AURKA AURKA ncbigene_symbol AURKA 6790
Homo sapiens Primates Akt AKT ncbigene_synonym AKT1 207
Homo sapiens Primates Akt AKT famplex_relations AKT2 208
Homo sapiens Primates Akt AKT famplex_relations AKT3 10000
Homo sapiens Primates IGFR1 IGFR1 ncbigene_synonym FCGR1A 2209
Homo sapiens Primates IGFR1 IGFR1 ncbigene_synonym FCGR1BP 2210
Homo sapiens Primates IGFR1 IGFR1 ncbigene_synonym FCGR1CP 100132417
Homo sapiens Primates IGFR IGFR ncbigene_synonym IGF1R 3480
Homo sapiens Primates NOTCH NOTCH famplex_relations NOTCH1 4851
Homo sapiens Primates NOTCH NOTCH famplex_relations NOTCH2 4853
Homo sapiens Primates NOTCH NOTCH famplex_relations NOTCH3 4854
Homo sapiens Primates NOTCH NOTCH famplex_relations NOTCH4 4855
Homo sapiens Primates ERa ERA ncbigene_synonym ESR1 2099
Homo sapiens Primates ERa ERA ncbigene_synonym ERAL1 26284
Homo sapiens Primates FGFR FGFR famplex_relations FGFR1 2260
Homo sapiens Primates FGFR FGFR famplex_relations FGFR2 2263
Homo sapiens Primates FGFR FGFR famplex_relations FGFR3 2261
Homo sapiens Primates FGFR FGFR famplex_relations FGFR4 2264
Homo sapiens Primates FGFR FGFR famplex_relations FGFRL1 53834
Homo sapiens Primates EGFR EGFR ncbigene_symbol EGFR 1956
Homo sapiens Primates NF1 NF1 ncbigene_symbol NF1 4763
Homo sapiens Primates RAS RAS famplex_relations KRAS 3845
Homo sapiens Primates RAS RAS famplex_relations HRAS 3265
Homo sapiens Primates RAS RAS famplex_relations NRAS 4893
Homo sapiens Primates GTP GTP ncbigene_synonym MTG1 92170
Homo sapiens Primates Raf RAF ncbigene_synonym ZHX2 22882
Homo sapiens Primates Raf RAF famplex_relations ARAF 369
Homo sapiens Primates Raf RAF famplex_relations BRAF 673
Homo sapiens Primates Raf RAF famplex_relations RAF1 5894
Homo sapiens Primates MEK MEK ncbigene_synonym MAP2K7 5609
Homo sapiens Primates MEK MEK famplex_relations MAP2K1 5604
Homo sapiens Primates MEK MEK famplex_relations MAP2K2 5605
Homo sapiens Primates mTOR MTOR ncbigene_symbol MTOR 2475
Homo sapiens Primates ERK ERK ncbigene_synonym EPHB2 2048
Homo sapiens Primates ERK ERK ncbigene_synonym MAPK1 5594
Homo sapiens Primates ERK ERK famplex_relations MAPK3 5595

Chemical mentions

Word Match MeSH Name ChEBI
ERa ERA chebi:51451
ERa ERA chebi:51451
RAS RAS (1R)-N-(prop-2-yn-1-yl)indan-1-amine chebi:63620
GTP GTP GTP chebi:37565
MEK MEK butan-2-one chebi:28398
ERa ERA chebi:51451
ERa ERA chebi:51451
ERa ERA chebi:51451
ERa ERA chebi:51451
Drugs drugs chebi:23888
Nucleus nucleus nucleus chebi:33252

Disease mentions

Word Match MeSH Name DOID